Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin

Inclusion criteria

• Male or female, able and willing to provide a written informed consent
• Diagnosed with type 2 diabetes ≥ 90 days；
• On stable once-daily dose of basal insulin alone or in combination with metformin and/or SGLT2 inhibitor ≥ 90 days;
• HbA1c was 7.5%~11.0% (both inclusive);
• Body Mass Index (BMI) ≥22 kg/m2 at screening.

Exclusion criteria

• A history of type 1 diabetes, specific diabetes, or secondary diabetes;
• Have a history of severe hypoglycemia within t180 days prior to screening;
• History of acute cardiovascular and cerebrovascular diseases within 180 days prior to screening；
• Have a history of malignancy within 5 years;
• Known or suspected allergy or intolerance to the investigational medicinal products or related products;
• Participation in any clinical trial of an approved or non-approved investigational product/treatment within the last 90 days;
• Any conditions that the Investigator judges might not be suitable to participate in the trial.